News & Awards

Press Releases

Latest News

April 18, 2023

Nitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting

March 28, 2023

Nitrase Therapeutics Presented New Findings on the Role of Synuclein Nitrase in Alpha Synuclein Nitration and Aggregation, as well as Motor Dysfunction at the 2023 Alzheimer’s & Parkinson’s Diseases (AD/PD) Conference

March 14, 2023

Nitrase Therapeutics to Present at the 2023 American Association for Cancer Research Annual Meeting

November 14, 2022

Nitrase Therapeutics Presented Data on the Importance of Synuclein Nitrase on the Synaptic Activity of Differentiated Dopaminergic Neurons at the Society for Neuroscience (SFN) Conference

October 31, 2022

Nitrase Therapeutics Presented Data on Role of Novel Nitrases in Regulating Known and Important Cancer Targets at EORTC-NCI-AACR Symposium

September 7, 2022

Nitrase Therapeutics Appoints Arun Kashyap, Ph.D., to Lead its Recently Launched Oncology Programs as Senior Vice President of Oncology

July 6, 2022

Nitrase Therapeutics Expands Leadership Team with Accomplished Drug Discovery and Development Executives

June 2, 2022

Nitrase Therapeutics Expands Pipeline to Include Oncology Programs and Adds Seasoned Cancer Experts to Scientific Advisory Board

April 5, 2022

Nitrase Therapeutics Receives New Grant from The Michael J. Fox Foundation for Parkinson’s Research

March 18, 2022

Nitrase Therapeutics Announces Major Discovery In Parkinson’s Disease Presented At The AD/PD International Conference

November 2, 2021

Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics

November 12, 2020

Nitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson

October 13, 2020

Nitrome Biosciences Appoints Industry Veteran Perry Karsen as Executive Chairman of the Board of Directors

April 21, 2020

Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases

@media (min-width:1042px){ #menu-primary-nav .sub-menu{ transition:transform 233ms 610ms, opacity 89ms calc(233ms + 610ms - 89ms) linear; } } @media (max-width:1041px){ #primary-navigation .menu-primary-nav-container{ -webkit-transition: -webkit-transform .233s ease-out, opacity .233s linear; transition: transform .233s ease-out, opacity .233s linear; } }